Abstract
High bleeding risk patients (HBR) are usually excluded from pre-approval drug-eluting stent trials (DES) and consequently the impact of gender on the long-term outcomes in HBR patients is unclear. We performed a patient-level pooled analysis of 4 all-comer real world post-approval registries (
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
